Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2022 - 2025)

Oramed Pharmaceuticals' Total Current Liabilities history spans 4 years, with the latest figure at $19.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities changed N/A year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, changed N/A, while the annual FY2025 figure was $19.1 million, N/A changed from the prior year.
  • Total Current Liabilities reached $19.1 million in Q4 2025 per ORMP's latest filing, up from $6.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $78.2 million in Q3 2023 to a low of $1.1 million in Q2 2023.
  • Average Total Current Liabilities over 4 years is $16.0 million, with a median of $6.1 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: soared 1098.08% in 2023, then tumbled 93.25% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $5.7 million in 2022, then soared by 826.11% to $53.2 million in 2023, then tumbled by 90.09% to $5.3 million in 2024, then skyrocketed by 261.96% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Total Current Liabilities are $19.1 million (Q4 2025), $6.1 million (Q3 2025), and $3.7 million (Q2 2025).